Elvina Almuradova, Medical Oncologist Ambassador at European School of Oncology, shared on X:
“PRECIOUS study:
Pertuzumab + trastuzumab retreatment
prolonged OS in HER2+ metastatic breast cancer!
OS: 36.2 months (PTC) vs. 26.5 months (TC)
PFS: investigator-assessed): 5.5 months (PTC) vs. 4.2 months (TC).”
